Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TMB Biomarker Is A Winding Path Rather Than Straight Road

Executive Summary

The tumor mutational burden biomarker had a much higher profile at this year's ASCO meeting, promising to help target treatment to individuals, though practical barriers remain and testing still is not ready for prime time yet.


Related Content

Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
First Expedited NGS Test Breaks Through FDA Review
Keytruda Approval Opens New Routes For Immuno-Oncology
Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Pharma trial needs drive Roche's $1.2bn Foundation Medicine deal


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts